Meda announced positive results from its Phase 3 trial of Dymista (azelastine HCl and fluticasone propionate) nasal spray in patients with seasonal allergic rhinitis. The randomized, double-blind, placebo-controlled, 2-week study was conducted in nearly 800 patients. The primary efficacy variable was the change from baseline in the 12-hour reflective Total Nasal Symptom Score (TNSS), consisting of nasal congestion, sneezing, itchy nose, and running nose. Data demonstrated that Dymista significantly improved the TNSS compared to placebo and either fluticasone or azelastine alone, during a 14-day treatment period.
For more information call (732) 564-2200 or visit www.medapharma.us.